Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China

Tianyu Feng, Zhou Zheng, Jiaying Xu, Peng Cao, Shang Gao and Xihe Yu ()
Additional contact information
Tianyu Feng: School of Public Health, Jilin University, Changchun 130012, China
Zhou Zheng: School of Public Health, Jilin University, Changchun 130012, China
Jiaying Xu: School of Public Health, Jilin University, Changchun 130012, China
Peng Cao: School of Public Health, Jilin University, Changchun 130012, China
Shang Gao: School of Public Health, Jilin University, Changchun 130012, China
Xihe Yu: School of Public Health, Jilin University, Changchun 130012, China

IJERPH, 2022, vol. 19, issue 16, 1-13

Abstract: Objective The aim of this study was to investigate the cost-effectiveness of Helicobacter pylori ( H. pylori ) screening and eradication treatment in an asymptomatic population in China and to explore the most cost-effective screening protocol for H. pylori . Method We used TreeAge 2019 to construct Markov models to assess the direct healthcare costs and quality-adjusted life years (QALYs) and the cost per year of life saved (YoLS) of three therapies, i.e., annual, triennial and five-yearly H. pylori screening. Excess probabilities were derived from published high quality studies and Meta-analyses, and costs and utilities were derived from the Chinese Yearbook of Health Care Statistics and published studies. Incremental cost-effectiveness ratios (ICERs) were used to describe the results. The willingness-to-pay threshold was set at China’s Gross National Product per capita. Result In the asymptomatic population, the ICER per QALYs gained was US$1238.47 and US$1163.71 for every three and five years of screening compared to the annual screening group; the ICER per YoLS gained was US$3067.91 and US$1602.78, respectively. Conclusion Screening for H. pylori in asymptomatic populations in China and eradicating treatment for those who test positive is cost-effective. Increasing screening participation in asymptomatic populations is more effective than increasing the frequency of screening. From a national payer perspective, it is cost-effective to screen the general asymptomatic population in China for H. pylori and to eradicate those who test positive. Individuals need to choose a screening programme that they can afford according to their financial situation.

Keywords: cost-effectiveness; gastric cancer; helicobacter pylori; Markov model; screening (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/16/9986/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/16/9986/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:16:p:9986-:d:887271

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().